Visgenx

Visgenx Appoints William Pedranti as Chief Executive Officer

by

The Company is developing VGX-0111, a gene therapy candidate for Dry Age-related Macular Degeneration (AMD), an aging related disorder and a leading cause of vision loss SAN DIEGO, June 5, 2023 /PRNewswire/ — Visgenx, Inc., a biotechnology company focused on developing gene therapies for degenerative retinal diseases, today announced the appointment of William Pedranti, J.D., … Read more

Visgenx to present at the American Society of Gene and Cell Therapy 2023 Annual Meeting

by

Poster presentation covers data on VGX-0111, the Company’s gene therapy candidate for Dry Age-related Macular Degeneration (AMD), an aging related disorder and a leading cause of vision loss SAN DIEGO, May 15, 2023 /PRNewswire/ — Visgenx, Inc., a biotechnology company focused on developing gene therapies for degenerative retinal diseases, today announced that the Company will … Read more